BCPT perspectives on studies involving natural products, traditional Chinese medicine and systems pharmacology.

Natural products constitute a vast source of bioactive compounds with the potential of providing valuable insight for future medicines. However, from a pharmacological perspective, natural product studies are also often accompanied by serious limitations due to, for example, the complex nature of biological extracts, the challenge of reproducibly characterizing the extract and providing an exhaustive list of constituents and, consequently, the difficulties in linking the observed pharmacological effects to specific chemical entities. The present paper discusses the major challenges of studies with natural products and provides a guideline to be followed by authors submitting research findings involving data from natural products, and their derivatives, to Basic & Clinical Pharmacology & Toxicology.

CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice.

Although current stem cell therapies exhibit promising potential, the extended process of employing autologous cells and the necessity for donor-host matching to avert the rejection of transplanted cells significantly limit the widespread applicability of these treatments. It would be highly advantageous to generate a pluripotent universal donor stem cell line that is immune-evasive and, therefore, not restricted by the individual's immune system, enabling unlimited application within cell replacement therapies. Before such immune-evasive stem cells can be moved forward to clinical trials, testing via transplantation experiments in immune-competent animals would be a favorable approach preceding preclinical testing.

Novel traceable CRISPR-Cas9 engineered human embryonic stem cell line (E1C3 + hSEAP + 2xKO + pCD47), has potential to evade immune detection in pigs.

Here we present the generation of a human embryonic stem cell line with the potential to escape immune rejection upon transplantation to an alternate species, in this case sus scrofa. For in vivo detection the cells were modified by CRISPR-Cas9 to express human secreted alkaline phosphatase. To avoid immune recognition and subsequent rejection by host, genes encoding hB2M and hCIITA were knocked out and the porcine gene for CD47 was introduced.

Validation of computed tomography as a diagnostic tool in guinea pigs with non-alcoholic fatty liver disease.

Non-alcoholic fatty liver disease (NAFLD) and subsequent steatohepatitis (NASH) is the most common cause of liver disease and liver transplantation in humans. Affecting millions of patients worldwide, diagnosis relies on a biopsy, not without risk to the patient, and emphasises the need for improved diagnostic measures to determine and monitor disease progression. Despite intensive research, approved pharmacological treatment modalities are few, underlining that animal models with increased translational validity are important to advance preclinical drug development.